A Retrospective Study of Medicare Claim Data Shows Patients Treated with Voraxaze® had Shorter Hospitalizations and Lower Mortality

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 02/14/2019.
  • Additional Information
    • Alternate Title:
      BTG-Plc
    • Subject Terms:
      United Kingdom; United States of America
    • Abstract:
      PHILADELPHIA, Feb. 14, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), the global healthcare company, today announced the publication of data showing that cancer patients with presumed methotrexate toxicity treated with Voraxaze® (glucarpidase) had shorter hospital stays, lower in-patient mortality, and lower 90-day mortality than those treated with conventional treatment. The study, based on a retrospective review of Medicare claim data, was published in the journal ClinicoEconomics and Outcomes Research. [ABSTRACT FROM PUBLISHER]